Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

Published Date: 11 Nov 2024

And nearly half of responders to enfortumab vedotin plus pembrolizumab remained in remission

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

2.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

3.

Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials

4.

In inflammatory breast cancer, ER beta regulates estrogen signaling.

5.

One-third of childhood cancer survivors experience significant fear that it could come back, study reveals


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot